当前位置： SCI文献检索 > PROSTATE CANCER AND PROSTATIC DISEASES期刊下所有文献 > Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients.

Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients.

Abstract：

:Increasingly animal and clinical studies suggest that intermittent therapy may improve the duration of hormone dependence in patients with prostate cancer. However there remains uncertainty as to optimal duration of treatment and level of prostate-specific antigen (PSA) before treatment is restarted. The aim of this study was to identify risk factors that predict duration of therapy in prostate cancer patients receiving intermittent hormone therapy. Any patients who had achieved PSA complete remission after hormone therapy for metastatic or locally advanced prostate cancer were included in the study. Fifty patients entered on intermittent hormone therapy after achieving a PSA complete remission. In all, 57% of patients remained off treatment at 12 months and the median time for restarting further hormone therapy was 14 months. At 1 y, 95% of patients retreated are progression free and overall 92% are alive at 3 y. There was some evidence that there was a slower progression to require treatment in older M0 patients and those who had been on treatment for more than 9 months. Although M0 patients receiving radiation concurrently after initial hormone down staging had a slower recurrence rate, 53% of M0 patients treated with hormone alone remained off hormones for more than one year. Clearly selection cannot be excluded as a cause for this good survival. However as overall survival in this study is at least as good as that of patients with M0 disease on hormone therapy in the immediate arm of the MRC immediate vs deferred therapy study, there is a case to extend examination of this approach to a randomized trial. This might also include patients failing to achieve PSA complete remission in order to examine the issue of whether continued androgen withdrawal is required in the terminal treatment phase of hormone-resistant patients to keep the hormone sensitive clone under control. Prostate Cancer and Prostatic Diseases (2000) 3, 286-289

journal_name

Prostate Cancer Prostatic Dis

journal_title

Prostate cancer and prostatic diseases

authors

Oliver RT,Farrugia D,Ansell W,Williams G,Chinegwundoh F

doi

10.1038/sj.pcan.4500483

subject

Has Abstract

pub_date

2000-12-01 00:00:00

pages

286-289

issue

4

eissn

1365-7852

issn

1476-5608

pii

4500483

journal_volume

3

pub_type

杂志文章

相关文献

PROSTATE CANCER AND PROSTATIC DISEASES文献大全
  • Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.

    abstract：:We hypothesized that factors beyond pathological stage, grade, PSA and margin status would be important predictors of biochemical recurrence (BCR) after radical prostatectomy (RP). A cohort of 3194 patients who underwent RP between 1988 and 2007 and who had neither neoadjuvant therapy nor postoperative adjuvant hormon...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2008.18

    authors： Schroeck FR,Sun L,Freedland SJ,Jayachandran J,Robertson CN,Moul JW

    更新日期：2008-01-01 00:00:00

  • Transrectal ultrasound imaging of the prostate: review and perspectives of recent developments.

    abstract：:We present a critical review of the recent literature and discuss the development and prospective view of the evaluations of transrectal ultrasound with regard to prostate malignancy. We illustrate this with personal experiences. Material and Methods: Based on a critical evaluation of clinical data we address the appa...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500326

    authors： Sedelaar JP,De La Rosette JJ,Beerlage HP,Wijkstra H,Debruyne FM,Aarnink RG

    更新日期：1999-12-01 00:00:00

  • The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.

    abstract：:The purpose of this study was to evaluate the relationship of baseline body mass index (BMI) and serum testosterone level with prostate cancer outcomes in men with castration-resistant metastatic prostate cancer (CRPC). BMI and testosterone levels were evaluated for their ability to predict overall survival (OS) and p...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2008.36

    authors： Armstrong AJ,Halabi S,de Wit R,Tannock IF,Eisenberger M

    更新日期：2009-01-01 00:00:00

  • Defining a role for the inhibitors of apoptosis proteins in prostate cancer.

    abstract：:The aim of this paper is to review the inhibitors of apoptosis proteins, a recently discovered group of caspase inhibitors. We will briefly review the relevance of apoptosis in prostate cancer and some of the control mechanisms, before describing the structure, function and regulation of these molecules. Lastly, we wi...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500502

    authors： McEleny KR,Watson RW,Fitzpatrick JM

    更新日期：2001-01-01 00:00:00

  • Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer.

    abstract：BACKGROUND:Understanding the mechanisms driving disease progression is fundamental to identifying new therapeutic targets for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). Owing to the prevalence of bone metastases in mCRPC, obtaining sufficient tumor tissue for analysis has histori...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2014.28

    authors： McKay RR,Zukotynski KA,Werner L,Voznesensky O,Wu JS,Smith SE,Jiang Z,Melnick K,Yuan X,Kantoff PW,Montgomery B,Balk SP,Taplin ME

    更新日期：2014-12-01 00:00:00

  • High level of dioxin-TEQ in tissue is associated with Agent Orange exposure but not with biochemical recurrence after radical prostatectomy.

    abstract：BACKGROUND:Agent Orange (AO) was previously identified as a significant risk factor for biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer patients. In this study, we determined the levels of dioxin biological toxicity using toxic equivalency (TEQ) values and examined the impact of dioxin-...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2013.33

    authors： Li Q,Lan L,Klaassen Z,Shah SR,Moses KA,Terris MK

    更新日期：2013-12-01 00:00:00

  • Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort.

    abstract：BACKGROUND:Approximately 29-38% of all positive surgical margins (PSMs) at radical prostatectomy (RP) involve the apex. The prognostic significance of apical PSM remains unclear. We therefore compared the long-term oncologic outcomes of men with apical PSMs to those with negative PSMs, apical and other PSMs, and other ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2016.45

    authors： Wadhwa H,Terris MK,Aronson WJ,Kane CJ,Amling CL,Cooperberg MR,Freedland SJ,Abern MR

    更新日期：2016-12-01 00:00:00

  • TGFBR1*6A is not associated with prostate cancer in men of European ancestry.

    abstract：:The TGFBR1*6A (*6A) variant in exon 1 of the TGFBR1 gene has been postulated as a putative tumor susceptibility allele in several studies. We have performed a case-control study in 537 men with histologically verified prostate cancer and in 488 unrelated controls to investigate the association of *6A with prostate can...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500765

    authors： Suarez BK,Pal P,Jin CH,Kaushal R,Sun G,Jin L,Pasche B,Deka R,Catalona WJ

    更新日期：2005-01-01 00:00:00

  • Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.

    abstract：INTRODUCTION:Approximately 85% of patients who die from prostate cancer present the spread of bone metastases. Even though the radiological appearance of such metastases is osteoblastic, it is now known that these lesions coexist in their microenvironment with blastic and lytic lesions. The process always begins with b...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500752

    authors： Rodrigues P,Hering F,Campagnari JC

    更新日期：2004-01-01 00:00:00

  • Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.

    abstract：:Side effects accompanying androgen deprivation therapy (ADT), including sarcopenia, loss of bone mass and reduction in muscle strength, can compromise physical function, particularly in older patients. Exercise, specifically resistance training, may be an effective and cost-efficient strategy to limit or even reverse ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500975

    authors： Galvão DA,Taaffe DR,Spry N,Newton RU

    更新日期：2007-01-01 00:00:00

  • Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.

    abstract：OBJECTIVE:To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs)-based prognosis. PATIENTS AND METHODS:A two-cohort-based evaluation for serum CGA for prognostication in C...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-018-0046-9

    authors： Giridhar KV,Sanhueza C,Hillman DW,Alkhateeb H,Carlson R,Tan W,Costello BA,Quevedo F,Pagliaro L,Kohli M

    更新日期：2018-09-01 00:00:00

  • Magnetic resonance imaging in prostate cancer.

    abstract：:With the recently published National Institute of Clinical Excellence guidelines, it is now generally accepted that magnetic resonance imaging (MRI) is the imaging method of choice for staging prostate cancer in patients for whom radical treatment is being considered. MRI offers the single most accurate assessment of ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500767

    authors： Heenan SD

    更新日期：2004-01-01 00:00:00

  • The role of external radiotherapy in patients treated with permanent prostate brachytherapy.

    abstract：:To examine the difference in Prostate Specific Antigen (PSA)-Relapse Free Survival (RFS) in patients (pts) with prostate cancer treated with permanent prostate brachytherapy (PPB) alone (monotherapy) or combined modality PPB and external radiotherapy (CMT) by a matched pair analysis. There were 1476 pts who were treat...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500552

    authors： Potters L,Fearn P,Kattan M

    更新日期：2002-01-01 00:00:00

  • Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia.

    abstract：:The purpose of the present study was to perform a BPH risk factor analysis in men, relating the prostate gland volume to components of the metabolic syndrome and to identify clues to the etiology of BPH. Our material comprised a consecutive series of 158 patients with lower urinary tract symptoms with or without manif...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500221

    authors： Hammarsten J,Högstedt B,Holthuis N,Mellström D

    更新日期：1998-03-01 00:00:00

  • Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer.

    abstract：BACKGROUND:To evaluate the safety and clinical feasibility of focal irreversible electroporation (IRE) of the prostate. METHODS:We assessed the toxicity profile and functional outcomes of consecutive patients undergoing focal IRE for localised prostate cancer in two centres. Eligibility was assessed by multi-parametri...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2014.33

    authors： Valerio M,Stricker PD,Ahmed HU,Dickinson L,Ponsky L,Shnier R,Allen C,Emberton M

    更新日期：2014-12-01 00:00:00

  • High-intensity interval training produces a significant improvement in fitness in less than 31 days before surgery for urological cancer: a randomised control trial.

    abstract：OBJECTIVES:To assess the efficacy of high-intensity interval training (HIIT) for improving cardiorespiratory fitness (CRF) in patients awaiting resection for urological malignancy within four weeks. SUBJECTS/PATIENTS AND METHODS:A randomised control trial of consecutive patients aged (>65 years) scheduled for major ur...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0219-1

    authors： Blackwell JEM,Doleman B,Boereboom CL,Morton A,Williams S,Atherton P,Smith K,Williams JP,Phillips BE,Lund JN

    更新日期：2020-12-01 00:00:00

  • Localized prostate cancer and 30 years of follow-up in a population-based setting.

    abstract：:Some patients with a histopathological diagnosis of prostate cancer have a tumour that behaves benignly during long-term follow-up. The proportion of patients with such a tumour is unknown, as is the fraction who die of prostate cancer between 10 and 20 y of follow-up. All men aged 45-84 y obtaining a diagnosis of pro...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500395

    authors： Adolfsson J,Oksanen H,Salo JO,Steineck G

    更新日期：2000-07-01 00:00:00

  • Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?

    abstract：:Prescription sales of testosterone have risen considerably over the last decade and are likely to continue to grow as further preparations become available. Testosterone promotes existing prostate cancer; however, concern does exist as to whether or not testosterone therapy induces prostate cancer. The aim of this art...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500839

    authors： Gould DC,Kirby RS

    更新日期：2006-01-01 00:00:00

  • Prevalence of prostatic intra-epithelial neoplasia (PIN) in biopsies from hospital practice and pilot screening: clinical implications.

    abstract：:As high grade PIN is commonly associated with concomitant cancer, current literature recommends re-biopsy of patients with high grade PIN. This paper describes the prevalence of high grade prostatic intra-epithelial neoplasia (PIN) from three independent clinical settings, reported by a single pathologist (MCP). High ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500210

    authors： Feneley MR,Green JS,Young MP,Bose P,Kirby RS,Peeling WB,Parkinson MC

    更新日期：1997-12-01 00:00:00

  • Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.

    abstract：:This study provides further insights into those preoperative parameters that predict side-specific risk of pathological stage in men undergoing radical prostatectomy (RP). The transrectal ultrasound-guided tissue biopsy cores obtained from the right and left sides of the prostate were collected in separate jars and ex...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2009.2

    authors： Sankin A,Tareen B,Lepor H

    更新日期：2009-01-01 00:00:00

  • The role of candidate genetic polymorphisms in the etiology of prostate cancer.

    abstract：:Prostate cancer appears to result from complex interactions among genetic, endocrine and environmental factors. Identification of risk factors for development and progression of prostate cancer is needed. This will allow researchers to design strategies to reduce the morbidity and mortality from this cancer and to ide...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500471

    authors： Neuhausen SL

    更新日期：2000-12-01 00:00:00

  • MRI in active surveillance: a critical review.

    abstract：INTRODUCTION:Recent technological advancements and the introduction of modern anatomical and functional sequences have led to a growing role for multiparametric magnetic resonance imaging (mpMRI) in the detection, risk assessment and monitoring of early prostate cancer. This includes men who have been diagnosed with lo...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/s41391-018-0077-2

    authors： Stavrinides V,Giganti F,Emberton M,Moore CM

    更新日期：2019-03-01 00:00:00

  • Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients.

    abstract：BACKGROUND:Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty as to which patients benefit from genomic testing and for whom these tests should be ordered. Here, we exami...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2016.38

    authors： Den RB,Santiago-Jimenez M,Alter J,Schliekelman M,Wagner JR,Renzulli Ii JF,Lee DI,Brito CG,Monahan K,Gburek B,Kella N,Vallabhan G,Abdollah F,Trabulsi EJ,Lallas CD,Gomella LG,Woodlief TL,Haddad Z,Lam LL,Deheshi S,Wa

    更新日期：2016-12-01 00:00:00

  • Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project.

    abstract：BACKGROUND:Several treatment options for clinically localized prostate cancer currently exist under the established guidelines. We aim to assess nationally representative trends in treatment over time and determine potential geographic variation using two large national claims registries. METHODS:Men with prostate can...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2015.3

    authors： Cary KC,Punnen S,Odisho AY,Litwin MS,Saigal CS,Cooperberg MR,NIDDK Urologic Diseases in America Project.

    更新日期：2015-06-01 00:00:00

  • A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.

    abstract：BACKGROUND:In men with high Gleason PC and rapid PSA progression after surgery, failure rates remain unacceptably high despite salvage radiation. We explored a novel multimodality approach of docetaxel with anti-angiogenic therapy before salvage radiotherapy (RT). METHODS:This was a phase 2 single-arm prospective open...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2015.59

    authors： Armstrong AJ,Halabi S,Healy P,Lee WR,Koontz BF,Moul JW,Mundy K,Creel P,Wood S,Davis K,Carducci MA,Stein M,Hobbs C,Reimer B,Nguyen M,Anand M,Bratt L,Kim S,Tran PT,George DJ,Department of Defense Prostate Cancer Cli

    更新日期：2016-03-01 00:00:00

  • The anticancer potential of metformin on prostate cancer.

    abstract：BACKGROUND:Prostate cancer (PCa) is characterized as the most frequent type of cancer in males. Recent research has suggested patients who have diabetes mellitus taking metformin (MF) have a lower risk of PCa. MF has antineoplastic effects such as adenosine monophosphate-activated protein kinase (AMPK)-dependent and in...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/s41391-018-0085-2

    authors： Zaidi S,Gandhi J,Joshi G,Smith NL,Khan SA

    更新日期：2019-09-01 00:00:00

  • Lack of survival benefit of post-operative radiation therapy in prostate cancer patients with positive lymph nodes.

    abstract：:Randomized data from SWOG 8794 and EORTC 22911 confirm the benefit of post-operative radiation therapy (RT) for selected patients with pT3 prostate cancer (CaP) after radical prostatectomy (RP). However, data regarding the potential benefit of RT for patients post-RP with positive lymph node (+LN) involvement are limi...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500940

    authors： Johnstone PA,Assikis V,Goodman M,Ward KC,Riffenburgh RH,Master V

    更新日期：2007-01-01 00:00:00

  • Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade.

    abstract：:Antiandrogen therapy is an important modality in the treatment of prostate cancer. Recent research into the role of angiogenesis in tumour growth and metastasis has uncovered links between antiandrogen therapy, radiation therapy and angiogenesis, which have exciting implications for the treatment of prostate cancer. A...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500779

    authors： Woodward WA,Wachsberger P,Burd R,Dicker AP

    更新日期：2005-01-01 00:00:00

  • Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.

    abstract：BACKGROUND:Patients with bone metastases secondary to prostate cancer are predisposed to skeletal-related events (SREs), including spinal cord compression, pathological fracture, surgery to bone and radiotherapy to bone. The objective of this study was to document current patterns of healthcare utilization and costs of...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2012.42

    authors： Hagiwara M,Delea TE,Saville MW,Chung K

    更新日期：2013-03-01 00:00:00

  • Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?

    abstract：:The relationships between serum level of testosterone (T) and prostate cancer (PCa) are complex. The present study evaluated whether presence of PCa alters serum T levels. Subjects were 125 patients with clinically localized PCa treated using radical prostatectomy (RP), for whom pretreatment T levels were recorded. We...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2008.35

    authors： Imamoto T,Suzuki H,Yano M,Kawamura K,Kamiya N,Araki K,Komiya A,Naya Y,Shiraishi T,Ichikawa T

    更新日期：2009-01-01 00:00:00